anne_beal_sanofi

Sanofi appoints a chief patient officer

pharmafile | April 2, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, anne beal 

Sanofi has hired Dr Anne Beal to the newly-created position of chief patient officer.

The move to hire such a head has not been seen elsewhere in pharma’s top 10 firms, and Sanofi’s executive VP of its global divisions and strategic development unit Pascale Witz, says it shows their commitment towards a patient-centred approach.

Beal’s responsibility will be to highlight patient perspective within the firm so that the company’s future products can better incorporate the unique priorities and needs of patients.

Advertisement

Beal is a pediatrician and joins Sanofi from the Patient Centered Outcomes Research Institute (PCORI). As PCORI’s deputy executive director, and its first chief officer for Engagement, she was charged with ensuring that the voices and priorities of patients and other stakeholders were reflected in the Institute’s research portfolio.

Prior to her tenure with PCORI, Beal was president of the Aetna Foundation, the independent charitable and philanthropic arm of Aetna. As president, she led the foundation’s work on improving health care in the US.

“I am incredibly honoured to join Sanofi as the first chief patient officer,” says Beal. “I will use my experience as a physician, researcher, philanthropic leader, and advocate for patient access to high quality care to infuse the patient perspective into Sanofi’s work.” 

Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …

The Gateway to Local Adoption Series

Latest content